Annovis Bio rises on clinical sites approval for Parkinson's disease study

Annovis Bio

08/02/2023 14:46

** Shares of drug developer Annovis Bio Inc  ANVS.N  rise 2%
to $19.31 in early trading
    ** Company gets approval for additional European clinical
trial sites for its ongoing late-stage study testing the use of
its lead compound, buntanetap, to treat Parkinson's disease, a
progressive disorder affecting the nervous system
    ** The approval adds 48 additional sites across Italy,
Spain, Hungary, Poland and Germany to an existing tally of 50
active sites - ANVS
    ** Based on the current enrollment, company anticipates
having a sufficient number of patients who have received two
months of therapy to conduct an interim analysis in Q2
    ** Stock has risen 26.5% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))